Aimed at controlling tumor angiogenesis, growth, and metastasis of MPM, nintedanib is a twice-daily (bid) oral triple angiokinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–3, platelet-derived growth factor receptors α/β, and fibroblast growth factor receptors 1–3, as well as Src and Abl kinases. The gene discussed is VEGFA; the disease is neoplasm.